WallStSmart

National HealthCare Corporation (NHC)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 3615% more annual revenue ($56.69B vs $1.53B). NVS leads profitability with a 22.5% profit margin vs 8.1%. NHC appears more attractively valued with a PEG of 0.82. NVS earns a higher WallStSmart Score of 51/100 (C-).

NHC

Buy

51

out of 100

Grade: C-

Growth: 6.0Profit: 6.0Value: 5.3Quality: 9.0
Piotroski: 5/9Altman Z: 3.70

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NHCSignificantly Overvalued (-71.1%)

Margin of Safety

-71.1%

Fair Value

$98.39

Current Price

$229.00

$130.61 premium

UndervaluedFair: $98.39Overvalued
NVSSignificantly Overvalued (-68.7%)

Margin of Safety

-68.7%

Fair Value

$92.54

Current Price

$158.83

$66.29 premium

UndervaluedFair: $92.54Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NHC3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.7010/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.828/10

Growing faster than its price suggests

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

NHC2 concerns · Avg: 4.0/10
P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
4.152/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NHC

The strongest argument for NHC centers on Debt/Equity, Altman Z-Score, PEG Ratio. PEG of 0.82 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bear Case : NHC

The primary concerns for NHC are P/E Ratio, Revenue Growth.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

NHC carries more volatility with a beta of 0.64 — expect wider price swings.

NHC is growing revenue faster at 2.2% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NHC scores higher overall (51/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

National HealthCare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

National HealthCare Corporation operates, manages, and provides services to skilled nursing facilities, assisted living facilities, independent living facilities, home health programs, and a behavioral health hospital. The company is headquartered in Murfreesboro, Tennessee.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?